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Abstract Differential tissue hypoxia drives normal car-
diogenic events including coronary vessel development.
This requirement renders cardiogenic processes potentially
susceptible to teratogens that activate a transcriptional
pathway that intersects with the hypoxia-inducible factor
(HIF-1) pathway. The potent toxin 2,3,7,8-Tetrachlo-
rodibenzo-p-dioxin (TCDD) is known to cause cardiovas-
cular defects by way of reduced myocardial hypoxia,
inhibition of angiogenic stimuli, and alterations in respon-
siveness of endothelial cells to those stimuli. Our working
hypothesis is that HIF-1 levels and thus HIF-1 signaling in
the developing myocardium will be reduced by TCDD
treatment in vivo during a critical stage and in particularly
sensitive sites during heart morphogenesis. This inadequate
HIF-1 signaling will subsequently result in outflow tract
(OFT) and coronary vasculature defects. Our current data
using the chicken embryo model showed a marked decrease
in the intensity of immunostaining for HIF-1a nuclear
expression in the OFT myocardium of TCDD-treated
embryos. This area at the base of the OFT is particularly
hypoxic during normal development; where endothelial cells
initially form a concentrated anastomosing network known
as the peritruncal ring; and where the left and right coronary
arteries eventually connect to the aortic lumen. Consistent
with this finding, anomalies of the proximal coronaries were
detected after TCDD treatment and HIF-1a protein levels
decreased in a TCDD dose-dependent manner.
Keywords Cardiovascular development  TCDD 
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Introduction
The contaminant 2,3,7,8-Tetrachlorodibenzo-p-dioxin (TCDD)
is a halogenated aromatic hydrocarbon that resists chemical
and biological degradation, thereby persisting in the environ-
ment and increasing the chances of human exposure. TCDD is
highly lipophilic, which promotes its bioaccumulation in the
food chain, leading to humans accumulating these chemicals
over a lifetime via a diet of meat, poultry, and dairy products,
mother’s milk, and to a lesser extent exposure from inhalation
of smog and cigarette smoke [1, 2]. Among the various adverse
effects caused by TCDD in animal experiments, its carcino-
genic effects have caused particular concern. TCDD does not
behave like a ‘‘complete carcinogen,’’ that is, no DNA binding
of the parent compound or metabolites could be detected.
However, enhanced oxidative damage of hepatic DNA was
observed, probably resulting from a dramatic induction of
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cytochrome P450 enzymes, which are under the regulatory,
transcriptional control of the TCDD-activated aryl hydrocarbon
receptor [2]. The chick embryo can be utilized as a highly
sensitive model to help elucidate the mechanism underlying
TCDD-induced cardiovascular toxicity during development
because under low levels of TCDD, it can still produce edema,
hemorrhage, and embryonic mortality [3, 25].
Studies using animal models provide evidence that the
vasculature is a target of TCDD and related chemicals, and
that toxicity is mediated by the activation of the aryl
hydrocarbon receptor (AhR). The AhR is a cytosolic,
ligand-activated transcription factor that belongs to the
basic helix-loop-helix-PAS (bHLH-PAS) superfamily of
DNA-binding proteins. TCDD binds the AhR with high
affinity and stimulates its translocation into the nucleus,
where it dimerizes with another bHLH-PAS protein,
ARNT (or HIF-1b). Although no specific genes involved in
angiogenesis or vasculogenesis have been identified to be
transcriptionally regulated by the AhR/ARNT complex,
other studies have suggested that sustained activation of the
AhR leads to changes in the expression of known angio-
genic stimuli [1]. TCDD inhibition of coronary develop-
ment is preceded by a decrease in myocyte proliferation
and an increase in cardiac apoptosis [4]; exogenous VEGF
rescues the inhibitory effect TCDD has on vasculogenesis
[5]; TCDD exposure reduces myocardial hypoxia and
VEGF expression [6] and also reduces endothelial cell
responsiveness to angiogenic stimuli [7]. These results are
consistent with the hypothesis that TCDD-activated AhR
may compete with the hypoxia-inducible factors for bind-
ing to the ARNT protein (Fig. 1).
HIF-1a expression levels have recently been shown to
play a role in not only the normal development of coronary
vasculature but also the development of potentially clini-
cally relevant coronary artery anomalies [8, 9]. The aim of
this study was to find evidence that TCDD might be
interfering with HIF-1-mediated transcriptional regulation.
Our working hypothesis is that HIF-1a levels and thus HIF-
1 signaling in the developing myocardium will be reduced
by TCDD treatment in vivo during critical stages in chick
heart morphogenesis and coronary vessel development.
This inadequate HIF signaling will in turn lead to the
misexpression of HIFs and abnormal coronary vasculature
development.
Materials and Methods
Preparation and Injection of Chicken Embryos
Plymouth Rock, Barred variety, or White Leghorn (Gallus
gallus) fertile chicken eggs (Privett Hatchery, Portales,
NM and Charles River-Avian Vaccine Services, CT) were
first weighed to determine the average and range of
weight for the preparation of the dosing solutions and then
incubated at 37.5 C at 55 % humidity in a forced-draft
JamesWay incubator under normoxic conditions (20.8 %)
until the embryos reached appropriate stages for each
experiment (HH 30 & 35) [10]. The eggs were placed on
an automatic rotator such that they were rocked back-and-
forth approximately once per every 2 h. Eggs were incu-
bated until day 4.5 (Stage 25) when they were removed
from the incubator and laid horizontally. The blunt end
was wiped with ethanol and a hole made in the shell into
the aircell with a sharp probe. The dosing solution
(vehicle control—corn oil, TCDD dissolved in corn oil)
was administered with a 100-ll gas tight Hamilton syringe
with a 26-g beveled removable needle. The needle was
inserted into the hole in the eggshell to *1 cm and 10 ll
of the dosing solution was dispensed into the aircell. The
egg was placed in a vertical position with the blunt end
upwards for further incubation. Dosings were with the
vehicle control of corn oil alone and 1.0 pmol and
3.0 pmol of TCDD/gm in 10 ll of corn oil. Stages of
experimental exposure were selected based on the results
from a previous publication to target stages of active
coronary vasculogenesis [9].
Immunohistochemistry
Embryos were fixed in fresh 4 % paraformaldehyde at 4 C
for 1 h, prepared for cryosection through a series of sucrose
solutions, frozen and cross-sectioned in either the frontal
or transverse plane. The 10–12-lm thick sections were
Fig. 1 Proposed intersection of the toxin and hypoxic pathway. Both
pathways require HIF-1b/ARNT
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collected on treated (Plus, Fisher) slides and immuno-
stained. The primary antibodies anti-HIF-1a (Gift of Dr.
Faton Agani) and anti-a-smooth muscle actin conjugated
with Cy3 (Sigma, St Louis, MO) were incubated overnight
at 4 C at a dilution of 1:500 and 1:400, respectively. Anti-
HIF-1a was detected with goat anti-rabbit IgG antibody,
conjugated with biotin (Vector, Burlingame, CA) at 1:200
dilution, and the signal was amplified with the TSA system
with fluorescent tyramide signal (PerkinElmer, Boston,
MA) per manufacturers instructions. Stained sections were
observed with an inverted fluorescence microscope (Nikon
Diaphot 200, Japan) or stereomicroscope (Leica MZ16F,
Leica Microsystems, Wetzlar, Germany) and images were
captured with a Q-Imaging Retiga EXi FAST 1394 digital
camera and Q-capture software (Q-Imaging Burnaby, BC,
Canada). Digital images were adjusted with Adobe
Photoshop CS5 software. Images of the negative controls
were captured with the same exposure as those of the
experimental samples at the same magnification and
adjusted in parallel.
Western Blots
Stage 30 embryonic chicken whole hearts were homoge-
nized with a sonicator under ice within an ice-cold lysis
buffer [50 mM Tris-HCl (pH 7.4), 150 mM NaCl, 1 % NP-
40, 1 % Triton X-100, 0.25 % Na-deoxycholate, 0.1 %
SDS, 1 mM EDTA, and a protease inhibitor cocktail
(Complete Mini, EDTA-free tablets (Roche, Mannheim,
Germany)] and stored in a -80 C freezer until needed.
Protein concentration was determined by using the DC
protein assay (Bio-Rad Laboratories Inc, Hercules, CA). A
total of 100 lg (50 mg for Tie2) of the whole heart protein
lysate was electrophoresed on an 8 % SDS–PAGE gel and
then transferred onto a polyvinylidenedifluoride (PVDF)
membrane (Millipore, Bedford, MA). Membranes were
blocked for 1 h at room temperature with 5 % nonfat milk
in Tris-buffered saline with 1 % Tween (TBST). The pri-
mary antibody rabbit polyclonal anti-HIF-1a (Gift of Dr.
Faton Agani) and rabbit polyclonal anti-Tie2 (Santa Cruz
Biotechnology, Inc) were incubated at a dilution of 1:500
and 1:1,000, respectively, overnight at 4 C. The mono-
clonal antibody anti-b-tubulin was used for the loading
control (1:100,000). After washing, the blots were incu-
bated with an anti-rabbit IgG (H&L) HRP-linked antibody
(Cell Signaling, Beverly, MA) for 1 h at room temperature
at a dilution of 1:5,000 (1:15,000 Tie2). Anti-mouse IgG
(H&L) HRP-linked antibody (Cell Signaling, Beverly,
MA) was used against b-tubulin at a dilution of 1:100,000
for 1 h at room temperature. Signals were detected using an
enhanced chemiluminescence detection system (ECL)
(Pierce Chemical Co., Rockford, IL).
Results
The hypothesis tested in this study is that TCDD may act to
alter coronary vessel development by reducing HIF-1a
nuclear localization and thus HIF-1 signaling in the
developing myocardium. HIF-1a nuclear-localized staining
was reduced markedly in most areas of the heart but most
notably in the stage 30 (ED 6.5) OFT myocardium under
3.0 pmol of TCDD (Fig. 2). These reductions within the
OFT myocardium were in the region where the left and
right coronary arteries will eventually attach to the aorta
(stage 32/ED 7.5). We also noted that there was an
increased level of positive HIF-1a nuclear-localized
immunostaining within the endocardial cushions near the
OFT of the stage 30 embryo. HIF-1a protein levels of
whole heart extracts at stage 30 qualitatively assessed by
Western blot analysis decreased. This decrease in HIF-1a
protein expression was TCDD dose-dependent. Quantita-
tive analysis of the Western blot analyses indicated that the
dose of 3.0 pmol but not 1.0 pmol of TCDD resulted in a
significant decrease in HIF-1a protein expression (Fig. 3).
We also found that the expression of the Tie2 protein at
stage 30 was decreased in a TCDD dose-dependent manner
(Fig. 3). Tie2 is important for the regulation of endothelial
cell differentiation during vascular remodeling and matu-
ration and although not a direct target of HIF-1a is an
indicator of vascular differentiation [11, 12].
Embryos were then exposed to a vehicle control, 1.0 or
3.0 pmol of TCDD/gm and incubated until stage 35 (ED 9)
to assay the anatomy of the proximal segments of the
coronary arteries. All but two embryos (2 out of 12) sur-
vived the vehicle control injections and these embryos
displayed no gross abnormalities when examined stereo-
scopically prior to dissection. All control embryos analyzed
in histological section (n = 10) displayed normal anatomy,
with neither coronary artery anomalies nor outflow tract
septal defects. A total of 7 of 12 embryos survived to stage
35 after exposure to 1.0 pmol of TCDD/g. These TCDD-
treated embryos exhibited no gross abnormalities as
viewed intact under the stereoscope. They appeared similar
in size and morphology with no noticeable defects similar
to the 10 surviving control injected embryos. However,
after transverse sections were stained for a-smooth muscle
actin and coronary arteries were examined, 1 of 7 embryos
displayed a coronary defect. The defect was a retro-aortic
branch off the left coronary artery that wrapped around the
aorta and inserted near the posterior cusp where there is
normally no coronary artery stem. This same embryo had a
septal defect of the OFT.
After injection of 3.0 pmol of TCDD/g, only 8 of 15
embryos survived to stage 35. Compared to control
embryos (n = 10), 3.0 pmol/g injected embryos had
increased mortality, hemorrhaging, and a failure of the
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body cavities to close. Examination of the sections
revealed coronary anomalies (5/8) and OFT septal defects
(4/8) in these treated embryos. All of the embryos had
some form of cardiac defect with 2 of 8 having both cor-
onary artery and septal defects of the OFT. There was a
coronary artery anomaly produced after a 3.0 pmol/g
exposure that was similar to an anomaly seen after a
1.0 pmol/g exposure. Many of the coronary anomalies
observed were of the retro-aortic type in which a coronary,
usually a branch off the left coronary artery, inserted back
Fig. 2 HIF-1a staining of control verses TCDD-treated embryos.
Specific sites of immunofluorescent staining for HIF-1a near the OFT
myocardium of a stage 30 chicken embryonic heart. HIF-1a nuclear-
localized immunostaining intensity and frequency was high in the
control (a–c) OFT myocardium (arrows in b, c) while lower in the
TCDD-treated embryos (f–h). However, TCDD-treated embryos had
increased HIF-1a staining within the endocardial cushions (g between
arrows, h). My myocardium and EC endocardial cushions. Bright
staining in d and h is autofluorescence of red blood cells and not that
of nuclear-localized HIF-1a staining
Fig. 3 HIF-1a and Tie2 protein
expression after TCDD
exposure. Protein expression as
qualitatively assessed by
Western blot decreased for both
HIF-1a and Tie2 after exposure
to 1.0 pmol and 3.0 pmol of
TCDD. Decreases in HIF-1a
were dose-dependent and were
not statistically significant until
embryos were exposed to
3.0 pmol of TCDD
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near the posterior cusp of the aorta. There were also mul-
tiple embryos that displayed double right coronary arteries
(Fig. 4; Table 1). In one case, there was a dilation of the
right coronary vessel at the point of connection with the
lumen of the aorta. The flat and irregular morphology of
these anomalous vessels resembled venous vessels rather
than arteries.
Discussion
TCDD treatment reduced the area of cells in the OFT
myocardium that was positive for nuclear-localized HIF-1a
as well as the overall level of HIF-1a. TCDD also caused
coronary anomalies that resembled those induced in a
previous study by altering the environmental level of
oxygen or by directly altering HIF-1a expression levels
using an engineered adenovirus vector [9]. These results
were consistent with our hypothesis (Fig. 1) that the
TCDD-activated AhR was competing with HIF-1a for
ARNT and was therefore preventing or displacing HIF-1a
from forming a stable heterodimer that could accumulate in
the nucleus with the resulting consequence that down-
stream vasculogenesis and angiogenesis factors failed to
regulate normal coronary vessel patterning. TCDD thus
may have altered the hypoxic template mediated by HIF-1.
The major difference between this study and a previous one
[9] was that in this study, HIF-1a levels were reduced
resulting in coronary artery anomalies as well as septal
defects. The previous study showed increases in HIF-1a
expression under adenovirus and hypoxic/hyperoxic con-
ditions and resulted in coronary artery anomalies as well.
The coronary anomalies in both studies displayed similar
patterns. This supports that deviation of proper HIF-1a
expression either up or down will result in coronary artery
anomalies.
Nascent coronary vessels begin to form at stage 27 and
attach to the systemic circulation by stage 32 [13]. A
capillary-like network (peritruncal ring) surrounds the base
of the outflow tract and select portions penetrate the aorta,
recruits smooth muscle cells, and emerges as two main
coronary artery stems connecting to the aorta [14, 15]. The
Fig. 4 Anatomy of the proximal coronaries after TCDD exposure.
Cryosections of hearts were immunostained with anti-smooth muscle
actin to identify coronary arteries. The pattern of the proximal
coronary arteries changed and septal defects were seen after a 3.0-
pmol exposure to TCDD. Coronary arteries and OFT septal defects
were observed in 1 of 7 embryos after a 1.0-pmol exposure to TCDD
(data not shown). After treatment with 3.0 pmol of TCDD, 5 of 8
embryos displayed coronary artery anomalies. The anomalies
included retro-aortic coronary (a, f), double right coronary (b, g),
or an incomplete lumen (c). 4 of 8 embryos displayed septal defects
(arrows in d) after exposure to 3.0 pmol TCDD. Diagrams of the
proximal attachments of the left and right coronary arteries in a stage
35 (ED 9) embryo were deduced from the observation of serial
transverse sections (e–g). Asterisks in c and g represent a sinus or
ampulla near the attachment of the right coronary artery to the aorta.
A Anterior, P posterior, L left, R right, Ao aorta, Pt pulmonary trunk,
LC left coronary, RC right coronary, RAD right anterior descending—
present in the chicken
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proximal segment of the coronary arteries develops by
endothelial ingrowth from the peritruncal ring rather than
by endothelial outgrowth from the aorta [14–16] and is
invariably located at the same locations relative to the
aortic leaflets. The mechanism that results in this stereo-
typed pattern of the proximal coronary arteries is unknown.
We previously showed that there is differential microen-
vironmental hypoxia in the developing heart creating a
‘‘hypoxic template’’ that precedes coronary vessel devel-
opment [8] and that HIF-1a regulation plays an important
part in the establishment of the proximal coronary artery
patterns [9]. With the addition of our TCDD data, there is
now another example correlating the disturbance of HIF-1a
nuclear expression and abnormal patterns of the proximal
coronary arteries.
In addition to coronary anomalies, TCDD also induced
outflow tract septal defects (Fig. 4) that we did not observe
with other methods of altering HIF-1a expression [9].
However, OFT abnormalities have been observed when
embryos were exposed to conditions that more severely
increased HIF-1a levels in the myocardium [17, 18]. These
abnormalities while striking were not primarily OFT septal
defects. We did note that HIF-1a levels within the mes-
enchymal cells of the outflow tract cushions were elevated
after TCDD treatment that may account for the failure or
delay of OFT septation. Thus, the outflow tract cushion
cells may also be affected by TCDD. Zebrafish embryos
exposed to TCDD are known to have abnormal outflow
tract development associated with abnormal function [19].
TCDD created proximal coronary anomalies located at
the base of the OFT and OFT septation defects. In view of
the location of these defects, it is relevant to note that the
gene expression of cytochrome P4501A4 that is induced by
TCDD-activated AhR is particularly concentrated in the
outflow tract myocardium after TCDD exposure [20, 21].
This region is also highly hypoxic as determined by
hypoxia indicator EF5 and HIF-1a immunostaining [8, 17,
22]. Thus, this region of the heart may be particularly
subject to the competition between AhR and HIF-1a for
ARNT (Fig. 1).
Our finding that vasculogenesis protein Tie2 levels
decreased with TCDD exposure (Fig. 3) is consistent with
findings from a recent report. In a study using the rat ani-
mal model, exposure to TCDD decreased the size of
maternal blood sinusoids, caused constriction of fetal
capillaries in the placenta, and a decreased expression level
of Tie2 mRNA [23]. Tie2 is an endothelial receptor tyro-
sine kinase which is highly expressed in endothelial cells
and its interaction with protein growth factors known as
angiopoietins shows that they play a crucial role in
remodeling and maturation of embryonic vasculature [24].
We used Tie2 as an indicator of vascular differentiation in
a previous study where we discovered that Tie2 protein
levels in embryo heart extracts increased significantly
along with HIF-1a levels under both hypoxic and hyper-
oxic conditions [9]. In the current study, we found the
opposite effect, TCDD exposure reduced Tie2 protein
levels along with HIF-1a levels thus supporting that dif-
ferentiation of coronary vessels was compromised.
Our findings support that coronary vessel anomalies
may result from TCDD exposure. While the TCDD-
induced anomalies in the avian model may have no impact
prior to hatching, we speculate that those that created sharp
angles and dilatations in the vessels may increase the risk
of ischemic heart disease, atherosclerosis, or coronary
aneurysms in later life.
TCDD exposure induced both coronary artery anomalies
and reduced HIF-1a protein expression. These results are
consistent with the hypothesis that competition between the
TCDD-activated AhR and HIF-1a for their heterodimer
Table 1 A Summary of dosage and mortality rates. B Summary of septal and coronary artery anomalies
Treatment Injected Collected Dead Description
A
Vehicle 12 10 (83 %) 2 (17 %) Normal
1.0 pmol of TCDD/g 12 7 (58 %) 5 (42 %) Similar to controls
3.0 pmol of TCDD/g 15 8 (53 %) 7 (47 %) Hemorrhaging and body
cavities failed to close
Treatment Septal defects Coronary anomalies Description
B
Vehicle 0/10 (0 %) 0 (0 %) Normal
1.0 pmol of TCDD/g 1/7 (14 %) 1/7 (14 %) Most are normal; retro-aortic coronary anomaly was
observed in one embryo along with a septal defect
3.0 pmol of TCDD/g 4/8 (50 %) 5/8 (63 %) All but one embryo was abnormal; retro-aortic and double
right coronary anomalies; flattened lumens; 2/8 embryos
had both septal and coronary defects
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partner ARNT (Fig. 1). Further mechanistic studies, per-
haps following the consequences of a knockout or knock-
down of the AhR, would be required to provide proof for
this hypothesis.
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